Biodesix, Inc., a molecular diagnostics company that discovers, develops and commercializes blood tests to deliver personalized medicine in oncology, announced today that the company increased the size of its offering of series F preferred shares in a follow-on sale, raising an additional $7 million.
The additional capital was provided by existing Biodesix investors and will be used for the development of new diagnostic tests for clinical use with immunotherapies, and the continued expansion of the company’s offering of its commercialized tests, VeriStrat® and GeneStrat™.
Biodesix, VeriStrat and GeneStrat are trademarks or registered trademarks of Biodesix, Inc. All other trademarks referenced herein are property of their respective owners.
Biodesix® is a molecular diagnostics company advancing the development of innovative blood-based tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including the GeneStrat and VeriStrat tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.